Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINIER Phase 3 study of povetacicept (ALPN-303) in adult IgA nephropathy
CTR20244331Phase 3Active
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Feb 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of povetacicept in IgA nephropathy (IgAN), sponsored by Alpine Immune Sciences, Inc.. Started Feb 2025; status: active.
02
Drugs
povetacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20244331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244331.